February 7, 2018 / 6:19 AM / 16 days ago

BRIEF-Targovax: Completion Of Safety Lead-In And Preliminary Immune Activation Data In ONCOS-102 Trial

Feb 7 (Reuters) - TARGOVAX ASA:

* REG-TARGOVAX ANNOUNCES COMPLETION OF SAFETY LEAD-IN AND PRELIMINARY IMMUNE ACTIVATION DATA IN ONCOS-102 TRIAL IN MESOTHELIOMA

* ‍DSMB HAVE RECOMMENDED THAT RANDOMIZED PART OF TRIAL CAN BE INITIATED​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below